- Details
- Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care. Biographies: Stefano Fanti, Professor Department of Experimental, Diagnostic and Specialty Medicine - DIMES...
|
- Details
- Stefano Fanti reviews the consensus paper on nuclear imaging for prostate cancer which was recently published in Lancet Oncology in December 2018. PSMA PET should be offered early in biochemical recurrence as it is the most sensitive and the EAU has incorporated PSMA PET into their guidelines as well, recommending PSMA PET for PSA >0.2. Stefano and Alicia discuss the various PSMA technologies and...
|
- Details
- Piet Ost shares details of his recent presentation focusing on biochemical recurrent prostate cancer, specifically in the recurrent setting, and answering the question such as should we be investing in this novel imaging for all patients or should we dial back a bit and only have that for selected patients? Who should get this imaging? He expressed his intent to try to convince people to think bef...
|
- Details
- Professor of Medicine Oliver Sartor from Tulane University joins Charles Ryan to discuss several lutetium studies, radioligand therapy, and the VISION trial and where the state of lutetium currently stands both in the United States and globally with radiopharmaceutical treatment options. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and...
|
- Details
- Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study is to compare the 2 alternative en...
|
- Details
- At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 meeting, Stefano Fanti presented the advantages of PSMA PET-CT in advanced prostate cancer imaging. He highlighted the role of PSMA PET-CT in staging, biochemical recurrence, and therapy planning. Biography: Stefano Fanti, MD, Professor, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Director of Nuclear Medic...
|
- Details
- Professor Ian Davis joins Carmel Pezaro to discuss the pitfalls of PSMA PET CT scans at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Starting the discussion on the disadvantages of PSMA PET, Professor Davis refers to PSMA PET as a bit of a mixed blessing and the challenge being the amount of enthusiasm for it and trying to bring it into clinical practice in a meaningful way. Wit...
|
- Details
- (Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...
|
- Details
- Professor Michael Hofman presented on prostate-specific membrane antigen (PSMA) targeted therapies during the Management of castration-resistant prostate cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, presenting data from both of his groups in Australia. Dr. Hofman highlights the progress of a single-centre, single-arm, phase 2 study; [177Lu]-PSMA-617 radi...
|
- Details
- Anwar Padhani presents at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 on imaging and flare responses when assessing patients with metastatic castration-resistant prostate cancer (mCRPC). In his presentation, Dr. Padhani notes that bone scans/CT scans lead to poor confidence for knowing the true clinical states and assessing therapy benefits for bone disease in advanced prostate...
|
